Frontlight ResearchEarly access
Not yet recruitingPhase 4
Aciclovir Versus Placebo for HSV-2 Meningitis
Key facts
- Who runs it
- Jacob Bodilsen
- Where
- Denmark8 sites in 1 countryChoose a country to see its sites
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Acyclovir 50 MG/ML
- Placebo
- Record updated
- 28 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:; A clinical presentation consistent with viral meningitis (e.g. headache, nuchal rigidity, photophobia, or fever) AND; Cerebrospinal fluid (CSF) pleocytosis (>4 leukocytes x 106/L) AND; HSV-2 positive by PCR of the CSF; Glasgow Coma Scale score of 15 AND; Ability to absorb oral medications
Who cannot take part
- Patients fulfilling any of the following criteria will be excluded:; Encephalitis as defined by the International Encephalitis Consortium if diagnosed during standard care (see Glossary)20; Transverse myelitis as defined by the Transverse Myelitis Consortium Working Group if diagnosed during standard care (see Glossary)21; Severe immuno-compromise defined as an ongoing need for biological- or chemotherapy (e.g. natalizumab), prednisolone >20 mg/day for ≥14 days, uncontrolled HIV/AIDS (see glossary), haematological malignancies, and organ transplant recipients14,18,22; Moderate to severe concomitant genital herpes requiring systemic aciclovir; Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women); Hepatic impairment (aspartate aminotransferase or alanine aminotransferase levels >5 times the upper limit of normal); Impaired renal function (estimated glomerular filtration rate <25 mL/min); Intolerance to (val)aciclovir; Probenecid treatment; Systemic antiviral therapy with an antiherpetic effect for >24 hours; Previous enrolment into this trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
The 2 groups in the trial
- Active armExisting treatment, for comparison
Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).
Treatment: Acyclovir 50 MG/ML
- PlaceboPlacebo, for comparison
Randomisation to 7 days of IV and/or oral placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)
- Record updated
- 28 October 2026